Patents by Inventor Gianni Motta
Gianni Motta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6680319Abstract: The invention relates to novel N-(substituted phenyl)-N′-[&ohgr;-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl]piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.Type: GrantFiled: January 17, 2002Date of Patent: January 20, 2004Assignee: Recordati S.A.Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi
-
Publication number: 20030181446Abstract: Described are novel N-acylated heterocycle derivatives having affinity for serotonergic receptors. These compounds and their enantiomers, diastercoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor.Type: ApplicationFiled: October 7, 2002Publication date: September 25, 2003Applicant: Recordati S.A.Inventors: Amedeo Leonardi, Gianni Motta, Rodolfo Testa, Carlo Riva, Jeffrey Corbett
-
Publication number: 20030162777Abstract: Described are compositions comprising a muscarinic receptor antagonist and an N-acylated heterocycle derivative having affinity for serotonergic receptors, and enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts thereof. The combination of a muscarinic receptor antagonist and an N-acylated heterocycle, or an enantiomer, diastereoisomer, N-oxide, polymorph, solvate or pharmaceutically acceptable salt thereof, is useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptors.Type: ApplicationFiled: October 7, 2002Publication date: August 28, 2003Applicant: Recordati S.A.Inventors: Amedeo Leonardi, Gianni Motta, Rodolfo Testa, Carlo Riva, Jeffrey W. Corbett, Per-Olof Andersson
-
Publication number: 20020193383Abstract: The present invention is directed to novel 1-(N-phenylaminoalkyl)piperazine derivatives substituted at the position 2 of the phenyl ring. Pharmaceutical compositions comprising the compounds of the invention also are contemplated. The compounds of the present invention also are contemplated for use in treating neuromuscular dysfunction of the lower urinary tract in a mammal.Type: ApplicationFiled: April 22, 2002Publication date: December 19, 2002Applicant: Recordati S.A., Chemical and Pharmaceutical ComoanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
-
Publication number: 20020193381Abstract: The invention is directed to compounds of Formula I: 1Type: ApplicationFiled: August 16, 2001Publication date: December 19, 2002Applicant: Recordati S.A. Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
-
Publication number: 20020183290Abstract: Described are derivatives with an adrenergic antagonistic activity and, in particular, high selectivity for &agr;1a- and &agr;1d-adrenergic receptors compared to &agr;1b-receptors. This selectivity profile suggests the use of these derivatives in the treatment of symptoms of the lower urinary tract, including those associated to benign prostatic hyperplasia, without the side effects associated with hypotensive activity.Type: ApplicationFiled: January 30, 2002Publication date: December 5, 2002Applicant: Recordati S.A., Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Rodolfo Testa
-
Patent number: 6486163Abstract: The invention relates to novel N-(substituted phenyl)-N′-[&ohgr;-(5-substituted-7-oxo-7H-thieno[3,2-b]pyran-3-carbonylamino)alkyl]piperazines their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neutogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.Type: GrantFiled: August 16, 2001Date of Patent: November 26, 2002Assignee: Recordati S.A. Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
-
Publication number: 20020161009Abstract: Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the &agr;1B-adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.Type: ApplicationFiled: August 22, 2001Publication date: October 31, 2002Applicant: Recordati S.A.Inventors: Amedeo Leonardi, Gianni Motta, Rodolfo Testa, Giorgio Sironi
-
Publication number: 20020161012Abstract: The invention relates to novel N-(substituted phenyl)-N′-[(&ohgr;-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl]piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.Type: ApplicationFiled: January 17, 2002Publication date: October 31, 2002Applicant: RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANYInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi
-
Patent number: 6403594Abstract: The invention relates to novel benzopyran derivatives of formula I, their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS), neurogenic lower urinary tract dysfunction (NLUTD), and other conditions.Type: GrantFiled: October 18, 2000Date of Patent: June 11, 2002Assignee: Recordati, S.A. Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Giorgio Sironi
-
Patent number: 6399614Abstract: The present invention is directed to novel 1-(N-phenylaminoalkyl)piperazine derivatives substituted at the position 2 of the phenyl ring. Pharmaceutical compositions comprising the compounds of the invention also are contemplated. The compounds of the present invention also are contemplated for use in treating neuromuscular dysfunction of the lower urinary tract in a mammal.Type: GrantFiled: March 21, 2000Date of Patent: June 4, 2002Assignee: Recordati S.A. Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
-
Patent number: 6387909Abstract: The invention relates to novel N-(substituted phenyl)-N′-[&ohgr;-(5-substituted-7-oxo-7H-thieno[3,2-b]pyran-3-carbonylamino)alkyl]piperazines their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD). The compounds are also useful in the treatment of excessive intraocular pressure, cardiac arrhythmia, erectile dysfunction, sexual dysfunction, and for inhibiting cholesterol synthesis or reducing sympathetically mediated pain.Type: GrantFiled: July 28, 2000Date of Patent: May 14, 2002Assignee: Recordati S.A. Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
-
Patent number: 6365591Abstract: The invention relates to novel N-(substituted phenyl)-N′-[&ohgr;-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl]piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions.Type: GrantFiled: October 18, 2000Date of Patent: April 2, 2002Assignee: Recordati, S.A., Chemical and Pharmacueticals CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi
-
Patent number: 6306861Abstract: The invention is directed to compounds of Formula I: wherein R is an aryl, cycloalkyl or polyhaloalkyl group, R1 is chosen from the group consisting of alkyl, alkoxy, polyfluoroalkoxy, hydroxy and trifluoromethanesulfonyloxy; each of R2 and R3 independently is chosen from the group consisting of a hydrogen, halogen, alkoxy and polyfluoroalkoxy group, and n is 0, 1 or 2. The invention further provides pharmaceutical compositions comprising a compound of Formula I or a N-oxide or pharmaceutically acceptable salt of such a compound in admixture with a pharmaceutically acceptable diluent or carrier. In another aspect, the present invention is directed to methods for selectively preventing contractions of the urethra and lower urinary tract, without substantially affecting blood pressure, by administering one or more selected compounds of Formula I to a mammal (including a human) in need of such treatment in an amount or amounts effective for the particular use.Type: GrantFiled: July 28, 2000Date of Patent: October 23, 2001Assignee: Recordati S.A. Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
-
Patent number: 6303606Abstract: Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the &agr;1B-adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.Type: GrantFiled: May 5, 2000Date of Patent: October 16, 2001Assignee: Recordati, S.A., Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Rodolfo Testa, Giorgio Sironi
-
Patent number: 6271234Abstract: Disclosed herein are novel compounds and methods for the treatment of disorders of the lower urinary tract. The novel compounds are 1,4-disubstituted piperazine derivatives. The methods comprise the administration of the novel compounds of the invention, and other compounds that bind to 5HT1A receptors, for treating disorders of the lower urinary tract.Type: GrantFiled: March 11, 1999Date of Patent: August 7, 2001Assignee: Recordati S.A., Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Luciano Guarneri, Elena Poggesi
-
Patent number: 6071920Abstract: Disclosed herein are novel compounds and methods for the treatment of disorders of the lower urinary tract. The novel compounds are aniline derivatives substituted at position 2 of the aniline ring. The methods comprise the administration of the novel compounds of the invention, and other compounds that bind to 5HT.sub.1A receptors, for treating disorders of the lower urinary tract.Type: GrantFiled: July 31, 1998Date of Patent: June 6, 2000Assignee: Recordati S.A. Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
-
Patent number: 5912351Abstract: The subject invention provides anhydrous 1,4-dihydropyridines and salts thereof, and a method for preparing them. The 1,4-dihydropyridines have Formula I: ##STR1## wherein: Ph is phenyl,Ar is: 2-nitrophenyl, 3-nitrophenyl, 2,3-dichlorophenyl or benzofurazan-4-yl,A is a branched chain alkylene radical having from 2 to 6 carbon atoms,R is a straight or branched chain alkyl radical having from 1 to 6 carbon atoms, optionally mono-substituted by an alkoxy substituent having from 1 to 6 carbon atoms,R.sub.1 is hydrogen, hydroxy, or an alkyl radical having from 1 to 4 carbon atoms, andR.sub.2 is hydrogen, or methyl.Type: GrantFiled: May 10, 1996Date of Patent: June 15, 1999Assignee: Recordati, S.A. Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta
-
Patent number: 5798362Abstract: New qunazolinyl-amino derivatives useful as .alpha..sub.1 -adrenoreceptor blockers are described. These compounds can be used as therapeutic agents for treating afflictions and diseases related to hyperactivity of the .alpha.-adrenergic system, such as, for example, arterial hypertension, prostate benign hyperplasia, high intraocular pressure and hpercholesterolemia. Processes for the preparation of the above said compounds are also described.Type: GrantFiled: September 17, 1996Date of Patent: August 25, 1998Assignee: Recordati S.A. Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Boi, Rodolfo Testa
-
Patent number: 5696139Abstract: The present invention provides S-enantiomers of 1,4-dihydropyridines useful for the treatment of heart failure, preparation of compositions thereof and a method for the treatment of hypertension and heart failure comprising administration of these compounds.Type: GrantFiled: May 9, 1996Date of Patent: December 9, 1997Assignee: Recordati S.A., Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Rodolfo Testa